Lunit Inc. (KOSDAQ:328130)

Market Cap	1.50T
Revenue (ttm)	54.18B
Net Income (ttm)	-82.42B
Shares Out	29.00M
EPS (ttm)	-2,858.00
PE Ratio	n/a
Forward PE	203.48
Dividend	n/a
Ex-Dividend Date	n/a

Volume	280,281
Average Volume	268,232
Open	52,600
Previous Close	51,500
Day's Range	51,500 - 53,700
52-Week Range	31,000 - 85,800
Beta	1.46
RSI	47.01
Earnings Date	May 14, 2025

About Lunit

Lunit Inc. provides AI-powered software and solutions for cancer diagnostics and therapeutics in South Korea. It offers AI solution for chest X-ray and mammography, as well as AI solution for digital breast tomosynthesis, and AI-powered biomarker for immune phenotyping and PD-L1 biomarker analyzer. The company has a strategic collaboration with AstraZeneca for the development of Lunit SCOPE Genotype Predictor, an AI-powered tool capable of analyzing H&E slide images to predict the likelihood of the tumor harboring NSCLC driver mutations, such a...

• Industry: Prepackaged Software
• Founded: 2013
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 328130

Financial Performance

In 2024, Lunit's revenue was 54.18 billion, an increase of 116.03% compared to the previous year's 25.08 billion. Losses were -82.42 billion, 124.0% more than in 2023.